LIFEVANTAGE CORP Increase (Decrease) in Deferred Revenue
LIFEVANTAGE CORP (LFVN) reported Increase (Decrease) in Deferred Revenue of $441.00 thousand for the 12-month period ending 2013-06-30, per its 10-K filed 2013-09-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2013-09-12
- LIFEVANTAGE CORP increase (decrease) in deferred revenue for the quarter ending 2012-09-30 was $188.00K.
- LIFEVANTAGE CORP increase (decrease) in deferred revenue for the quarter ending 2011-09-30 was -$3.00K.
- LIFEVANTAGE CORP increase (decrease) in deferred revenue for fiscal 2013 was $441.00K, a 126.15% increase from fiscal 2012.
- LIFEVANTAGE CORP increase (decrease) in deferred revenue for fiscal 2012 was $195.00K.
- LIFEVANTAGE CORP increase (decrease) in deferred revenue for fiscal 2011 was -$6.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 12 month | Increase (Decrease) in Deferred Revenue 12 month as first filed |
|---|---|---|---|
| 2013-06-30 | $441.00K 10-K · filed 2013-09-12 | ||
| 2012-09-30 | $188.00K 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $195.00K 10-K · filed 2013-09-12 | $195.87K 10-K · filed 2012-09-10 | |
| 2011-09-30 | -$3.00K 10-Q · filed 2012-11-08 | ||
| 2011-06-30 | -$6.00K 10-K · filed 2013-09-12 | -$6.17K 10-K · filed 2012-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |